The patients evaluated for irH are cancer patients who may have non-specific symptoms such as fatigue, weight loss, anorexia, etc. and may be on therapies that can affect hormonal work up such as GnRH agonists and glucocorticosteroids. This evidence concerns the gene GNRH1 and cancer.